Abstract In two siblings, who suffer from an early childhood-onset axonal polyneuropathy with exclusive involvement of motor fibers, the c.629T>C (p.F210S) mutation was identified in the X-linked AIFM1 gene, which encodes for the apoptosis-inducing factor (AIF). The mutation was predicted as deleterious, according to in silico analysis. A decreased expression of the AIF protein, altered cellular morphology, and a fragmented mitochondrial network were observed in the proband's fibroblasts. This new form of motor neuropathy expands the phenotypic spectrum of AIFM1 mutations and therefore, the AIFM1 gene should be considered in the diagnosis of hereditary motor neuropathies.
Introduction
Inherited peripheral neuropathies (IPNs) are a group of disorders clinically and genetically highly heterogeneous. Mutations associated with IPNs in more than 80 genes have been already reported (http://neuromuscular.wustl.edu/). Hereditary motor and sensory neuropathy or Charcot-MarieTooth (CMT) disease are closely related to distal hereditary motor neuropathy and, occasionally, some patients show additional disorder-related signs of amyotrophic lateral sclerosis or spinal muscular atrophy. Therefore, in some cases, the genetic, clinical, and biochemical overlapping among IPNassociated genes can extremely complicate the differential diagnosis.
When the most common genes are discarded by conventional methods, targeted resequencing with a gene panel is considered as a very powerful and cost-effective tool for diagnosis of inherited peripheral neuropathies [1, 2] . Using a Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10048-017-0524-6) contains supplementary material, which is available to authorized users. gene panel that comprises 104 genes involved in CMT and related neuropathies, the novel AIFM1 c.629C>T (p.F210S) mutation was identified in two brothers affected by an early childhood-onset polyneuropathy with exclusive motor involvement.
The AIFM1 gene encodes the apoptosis-inducing factor (AIF), a mitochondrial FAD-dependent protein, and beyond its role in apoptosis, AIF takes part in mitochondrial metabolism [3] [4] [5] . AIFM1 mutations are associated with a wide spectrum of clinical entities with recessive X-linked inheritance, including mitoc h o n d r i a l e n c e p h a l o m y o p a t h y [ 6 ] , p r e n a t a l ventriculomegaly [7] , Cowchock syndrome [8] , auditory neuropathy spectrum disorder [9] , mitochondrial encephalomyopathy with ventriculomegaly [10] , and spondyloepimetaphyseal dysplasia with mental retardation [11] . This new case broadens the clinical spectrum of the AIFM1-related disorders.
Methods

Patients
Patients 1 (II:1) and 2 (II:2) are brothers, born to healthy unrelated parents of Bulgarian origin ( Supplementary  Fig. 1 ). Their main complaint was progressive distal limb weakness that evolved over the years in a lengthdependent manner, with normal cognitive function. Blood samples and skin biopsies were obtained under approved institutional review board protocols and informed consent was obtained from all individual participants included in the study.
Genetic and in silico analysis
Patient 1 was investigated by gene panel Neuro104 (Supplementary Data) based on SureSelectQXT technology (Agilent Technologies, Santa Clara, CA, USA) for Illumina (San Diego, CA, USA). Sanger sequencing on an ABI Prism 3130XL analyzer (Applied Biosystems, Foster City, CA, USA) was performed for validation and segregation analysis. To investigate the novelty of the variants, several databases were consulted (gnomAD, ClinVAR, and HGMD). Conservation of the residues was analyzed using Clustal Omega, GERP, and PhyloP algorithms and the pathogenicity was predicted using SIFT, PolyPhen-2, PROVEAN, and MutationTaster algorithms. The mutated protein was modeled by Coot software, using the structures 4BUR and 4BV6 (RCBS Protein Data Bank), which correspond to the human AIF in complex with FAD and with FAD and NAD, respectively.
Cell culture, immunofluorescence, western blot, and qPCR Skin-cultured fibroblasts derived from patients and their matched controls were grown in basal DMEM medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% (v/v) fetal bovine serum and supplemented with 2 mM glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA).
For immunofluorescence, cells were fixed in 4% paraformaldehyde and permeabilized in 0.25% Triton X-100. Subsequently, cells were blocked and immunostained in 5% horse-serum and finally, assembled with Vecta-Shield Mounting Medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). Images were visualized using a SP2-or SP8-Leica confocal microscope (Leica, Wetzlar, Germany). Anti-TOMM20 (Millipore, Bedford, MA, USA) was used at 1/250 dilution for mitochondria localization. The microfilament marker anti-actin (Sigma-Aldrich, St. Louis, MO, USA) was also used at 1/250 dilution to assess cell morphology changes.
Western blot analysis was performed by standard procedures, using fibroblasts' lysates (25 μg protein per well), anti-AIF (at 1/500 dilution), and anti-actin (at 1/4000 dilution). Quantitative real-time PCR (qPCR) was performed using SYBR® Green (Quanta Biosciences, Gaithersburg, MD, USA) in a LightCycler® 480 Instrument (Roche, Indianapolis, IN, USA). Results were normalized by using the reference gene GAPDH. Side chain of some relevant residues are shown and labeled. c Western blot analysis of the patient (Pt) and two controls (Ct1: female; Ct2: male) fibroblasts' lysates, immunodetected with an antibody against AIF; histograms represent relative protein quantification of AIFM1. Error bars represent SEM. Student's t test *p < 0.05 and **p < 0.01 (n = 9). d Immunofluorescence of the Pt's fibroblasts compared to Ct using the microfilament marker anti-actin. e Apoptotic assay at different times (3 and 6 days), using annexin V-FITC as an apoptotic marker. f Representative images of mitochondrial morphology marked with anti-TOMM20, showing the filamentous (Ct) of the fragmented (Pt) of fibroblasts. g Quantification of fibroblasts with a normal (Ct) or fragmented (Pt) mitochondrial network. Error bars represent SEM. Student's t test ***p < 0.001 (n = 3) b
Apoptosis measurements
Fibroblasts were grown in basal DMEM medium during 3 or 6 days. Cells were detached from the culture flask using 0.05 trypsin-EDTA and then centrifuged at 300g for 5 min. After washing the cells with cold PBS, they were labeled for 15 min in the darkness with 5% annexin V-FITC (BioLegend, San Diego, CA, USA) in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) and apoptosis measurements were performed in a FC500 MPL Flow Cytometer (BeckmanCoulter Inc., Brea, CA, USA).
Measurement of an interconnectivity index of cellular mitochondrial networks
A total of 150 cells per genotype were used to quantify the main area/perimeter ratio after growing for 48 h in basal DMEM medium [12] . MitoTracker® Red CMXRos (Thermo Fisher Scientific, Waltham, MA, USA) was used for labeling mitochondria.
Results
Patients' history and electrophysiological data
In both patients ( Supplementary Fig. 1 ), electrophysiological studies revealed an axonal polyneuropathy with predominant involvement of motor fibers. Sensory amplitude measurements were within the normal range (Table 1) .
Patient 1 is a 13-year-old boy. Motor milestone acquisition was normal during the first year of life, but at 16 months of age, he was still unable to walk independently. Weakness in ankle dorsiflexion and areflexia were also noticed. At 5 years, thigh muscles were mildly affected, as well as both hands. When he was 6 years, walking was achieved due to knee-ankle-foot orthoses, but he lost ambulation at 11 years. Patient 2 is an 8-year-old boy. At 18 months of age, he had walking difficulties. He achieved independent ambulation beyond 2 years. By then, he showed weakness and atrophy restricted to the distal muscles of lower limbs. Proximal muscles became affected later and both hands showed progressive weakness and wasting. He walks with ankle-foot orthoses and is still able to climb stairs while holding on to a rail.
Genetic and in silico analyses
After genetic testing using panel Neuro104 in patient 1, the only candidate change to be the disease-causing mutation is a novel variant in AIFM1, c.629T>C (p.F210S) in hemizygosis (Supplementary Table 1 ). In addition, two other variants, GNB4 c.186T>C (p.H62H) and DGAT2 c.690T>C (p.S230S), were detected in heterozygosis but classified as likely benign because they are synonymous and their allele frequencies are greater than expected for disorder (Supplementary Table 1) . Patient 2 and the healthy mother carry the AIFM1 mutation, whereas the patients' father does not harbor it. The F210 residue is highly conserved through evolution ( Supplementary Fig. 3a) , and in silico prediction tools classified AIF F210S as damaging ( Supplementary  Fig. 3b) . Analysis of the crystal structure of human AIF shows that F210 is localized in an alpha-helix of the protein surface (Fig. 1a) , with its side chain stacking with P207, and taking part of a region with predominant hydrophobic interactions, which also involves the side chains of Q206, F205, and F144 (Fig. 1b) that seems to generate a quite compacted structure. The mutation of a phenylalanine to serine at position 210 would disrupt the hydrophobic interactions possibly destabilizing the alpha-helix and consequently the position of the β-hairpin (residues 192-204), which participates in NAD binding. In addition, superposition of the two different human AIF structures (Fig. 1a, b) suggests that a lack of constraints in this region could also affect the interaction of this hairpin and the regulatory peptide (residues 510-560) [13] , which has been associated with the functional activity of AIF. The qPCR assay showed comparable mRNA levels between mutant and control fibroblasts ( Supplementary Fig. 4) ; however, the western blot analysis shows decreased levels of AIF in the patient compared to controls, which are statistically significant (Fig. 1c) .
Functional analyses
We have investigated the morphology of the patient's fibroblasts, which reveals cells with irregular and stellate outlines with cytoplasmic connections ( Fig. 1d;  Supplementary Fig. 2 ). However, in the apoptotic assay, no significant differences are observed in the patients' fibroblasts compared to the healthy control ones (Fig.  1e) . On the other hand, using a specific antibody to detect the mitochondrial protein TOMM20, we find fragmentation of the mitochondrial network (Fig. 1f) . To confirm and to quantitatively assess it, we used the average area/perimeter ratio in which lower values indicate increased mitochondrial fragmentation [12] . Thus, the mutant cells exhibit a statistically significant decrease of this rate (Fig. 1g) , which supports the occurrence of mitochondrial fragmentation.
Discussion
The variability of the AIFM1 mutations leads to a broad range of complex clinical presentations [6] [7] [8] [9] [10] [11] . The patients here described suffer from an early childhood-onset axonal polyneuropathy with exclusive involvement of motor fibers and have showed normal cognitive function, thus expanding the clinical spectrum of AIMF1-related diseases. These data suggest that the AIFM1 gene should be considered in the diagnosis of hereditary motor neuropathies.
Several cell alterations have been described in patients with AIFM1 mutations. Thus, the p.E493V mutation increases caspase-independent apoptosis [8] , while the p.R201del mutation leads to impaired OXPHOS [6] . Although none of these two mutations alter AIF levels [6, 8] , others (p.V243L, p.G262S, or p.G338E) decrease it [10, 13, 14] . For the new mutation here reported, AIFM1 p.F210S, the genetic and in silico analyses indicate that is likely deleterious. The analysis of the crystal structure of AIF reveals that the mutation p.F210S would destabilize the interaction between the region 510-516 and the β-hairpin, which is relevant for the proper function of AIF. While mRNA levels are unchanged, the AIF F210S expression is downregulated suggesting lower protein stability. The mutation does not increase apoptosis, and in patients' fibroblasts, an ab normal m o rpho lo gy is obser ved. Moreo ver, fragmented mitochondria are detected, which could be related to a faulty mitochondrial respiration [15] . Importantly, to achieve definite findings, it would be useful to replicate these approaches in additional unrelated patients' fibroblasts. Further mitochondrial respiratory chain activity experiments such as NAD-binding assays would contribute to delineate the pathomechanism for this mutation.
In summary, these findings emphasize that AIF is involved in several and relevant cell functions and the distinct effects of different AIFM1 mutations could explain the variable clinical outcome. Thus, a strong decrease in the protein levels and/or in respiratory function would develop an early and severe mitochondrial disease, whereas weaker impairments would cause a slowly progressive neurological picture [13] . Based on the results shown here, our patients, who suffer from a severe early-onset motor neuropathy without cerebral involvement, could belong to the first group of AIFM1 disorders.
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